| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers T > Headlines for Trimeris, Inc. > News item |
Trimeris, Roche unveil two HIV fusion inhibitor drug candidates
By Ted A. Knutson
Washington, Jan. 17 -Trimeris, Inc. and Roche announced Tuesday the selection of two next-generation fusion inhibitor peptides for co-development and progression into further pre-clinical studies in the development and commercialization of fusion inhibitors for the treatment of HIV/AIDS.
The peptides, TR-291144 and TR-290999, first synthesized at Trimeris, are distinct compounds derived from HR2 sequences of HIV.
In connection with this event, Trimeris will receive a payment from Roche.
TR-291144 and TR-290999 are being developed with the specific goal of achieving durable suppression of HIV by increasing the potency of the molecules and raising their genetic barrier to the development of resistance. Also central to the development program is increased patient convenience via simpler, more patient-friendly administration, with a target of once-weekly dosing.
"The future of these new fusion inhibitor peptide candidates is quite promising," said Nick Cammack, Ph.D., vice president and head of viral diseases research at Roche, in a news release. "The development announced today is reflective of our continued commitment to developing new strategies to help manage patients with HIV."
"We are very encouraged by the prospect of co-developing the next generation of fusion inhibitor peptides with our colleagues at Roche," said Trimeris CEO Steven D. Skolsky in a news release. "This is a significant milestone which further validates our peptide technology platform."
Roche and Trimeris currently market Fuzeon (enfuvirtide), the first and only fusion inhibitor available for the treatment of HIV.
Morrisville, N.C.-based Trimeris is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.